ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc (LBPH)

19.85
0.60
( 3.12% )
Updated: 12:50:44

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
19.85
Bid
19.63
Ask
19.85
Volume
80,658
18.865 Day's Range 19.86
3.60 52 Week Range 28.15
Market Cap
Previous Close
19.25
Open
19.25
Last Trade
10
@
19.8
Last Trade Time
12:51:59
Financial Volume
$ 1,563,194
VWAP
19.3805
Average Volume (3m)
543,237
Shares Outstanding
36,017,249
Dividend Yield
-
PE Ratio
-13.02
Earnings Per Share (EPS)
-1.51
Revenue
-
Net Profit
-54.42M

About Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659. Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Longboard Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LBPH. The last closing price for Longboard Pharmaceuticals was $19.25. Over the last year, Longboard Pharmaceuticals shares have traded in a share price range of $ 3.60 to $ 28.15.

Longboard Pharmaceuticals currently has 36,017,249 shares outstanding. The market capitalization of Longboard Pharmaceuticals is $708.82 million. Longboard Pharmaceuticals has a price to earnings ratio (PE ratio) of -13.02.

LBPH Latest News

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the...

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) was reported in January Announcing an update to the...

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that...

Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.1612.210288298517.6920.7217.3141766618.98345211CS
4-2.05-9.3607305936121.921.916.5539113118.75759926CS
12-0.82-3.9671020803120.6724.516.5554323720.10307481CS
2614.43266.2361623625.4228.153.684769722.47590504CS
5212.58173.0398899597.2728.153.646687920.99094694CS
1569.7596.534653465310.128.152.717597419.28047548CS
2603.8524.06251628.152.717369419.20158602CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.175
(62.11%)
60.73M
NUZENuZee Inc
$ 1.89
(54.92%)
1.02M
NIVFNewGenIvf Group Ltd
$ 1.85
(42.31%)
52.82M
PEGYPineapple Energy Inc
$ 0.0731
(40.85%)
274.63M
ULHUniversal Logistics Holdings Inc
$ 45.69
(38.92%)
345.14k
ISUNiSun Inc
$ 0.1517
(-95.60%)
8.26M
MFImF International Ltd
$ 2.5001
(-76.05%)
14.09M
NWGLNature Wood Group Ltd
$ 5.00
(-70.33%)
1.54M
ICLKiClick Interactive Asia Group Ltd
$ 1.325
(-47.63%)
609.81k
NUWENewellis Inc
$ 0.1735
(-39.97%)
16.14M
PEGYPineapple Energy Inc
$ 0.0731
(40.85%)
274.63M
SQQQProShares UltraPro Short QQQ
$ 11.385
(-5.13%)
92.27M
INTCIntel Corporation
$ 31.69
(-9.74%)
76.54M
TSLATesla Inc
$ 171.4995
(0.78%)
61.07M
BDRXBiodexa Pharmaceuticals PLC
$ 1.175
(62.11%)
60.73M

LBPH Discussion

View Posts
da_stock_analyst da_stock_analyst 4 months ago
#LBPH 🔥 short squeeze might push this way higher! Nice set up!
👍️0
Backstabbed Backstabbed 4 months ago
Insane … grats all
👍️0
conix conix 4 months ago
LOTTO Ticket for 2024: Curative Biotechnology $CUBT @ $0.02 is a biotech with some very promising technology in the treatment of Age-Related Macular Degeneration (AMD). Metformin, a widely used diabetes drug, has been proven to have positive effects on patients with AMD. CUBT has a patented formulation for the direct delivery of metformin to the eye in the form of eye drops. The National Institutes of Health (NIH) will be funding a clinical trial on humans in 2024 in collaboration with the company. There has been a number of delays in the start of the trials, hence the low price, but the price has been firming up this past month. Although difficult to predict when these announcements happen, at these prices, CUBT is worth buying a small position (you can define "small") to make certain you are following the news and the price reaction so you can average up on your original position. Check the CUBT website out to see more info on the trials and the company's other drugs in the pipeline. Target Price by end of First Quarter (assuming clinical trial announcement)--$0.15).

SOURCE: https://www.reddit.com/r/pennystocks/comments/18uvm1j/trading_ideas_for_january_sing_migi_cubtmentioned/

It should go without saying, BUT some may need to read it...the above is someone's opinion. Nice to see anyways.
👍️0
conix conix 4 months ago
Congrats on being a quick thinker. Per-market buying can be risky, but does pan out.
👍️0
TheFinalCD TheFinalCD 4 months ago
The company has 9.5 months of cash left based on quarterly cash burn of -$13.28M and estimated current cash of $42.0M.
https://dilutiontracker.com/app/search/LBPH?a=dbb88c
👍️0
Stockexpertpro Stockexpertpro 4 months ago
AVTX Data Due on Watch here after 1 for 240 RS micro Float
👍️0
Laster Laster 4 months ago
Grabbed some at 8am immediately following news.
Looking good moving into open.
Sold half on double. Riding rest free.
What a way to start 2024!
👍️0
Monksdream Monksdream 4 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
tw0122 tw0122 4 months ago
An epileptic profit nice…
👍️0
cityimport cityimport 4 months ago
My First Almost 200% Profit (Within One Hour) In 2024 ... :)))))))))))))

In @ 6.25
Out @ 17.95

LBPH
👍️0

Your Recent History

Delayed Upgrade Clock